Intradiscal drug delivery system for the treatment of low back pain
Intradiscal drug delivery system for the treatment of low back pain
复制标题
DOI：
10.1002/jbm.a.32377
复制
发表时间：
2010-01-01
影响因子：
4.9
通讯作者：
Park, Joon B.
中科院分区：
文献类型：
--
作者：
Lee, Jin Whan;Lim, Tae-Hong;Park, Joon B.
长期控制腰痛（LBP）的可能解决方案是使用可局部注射的止痛药载体。这种药物可以以可控的方式释放。它也允许反复注射更多的药物，以最小的侵入。本研究的主要目的是开发这样一种药物输送系统（DDS）来长期控制椎间盘源性腰痛。DDS由含有微球（MS）的原位形成水凝胶基质（Pluronic F127 (R)加透明质酸钠）组成。固体质谱用于药物的长期释放。水凝胶基质和质谱均含有一种模型药物布比卡因碱（BB）。可以通过改变水凝胶的组成来控制相变（室温下的液体，体温附近的凝胶）。体外实验表明，在42天内，约3% （w/w）的BB被加载到MS中，表明布比卡因具有良好的缓释潜力。(C) 2009 Wiley期刊公司[J] .生物医学工程学报，2009,31 (2):387 - 398
Possible solution to the long-term control of the low back pain (LBP) would be by using an injectable pain drug carrier that can be delivered locally. The drug can be released in a controlled manner. It is also allowed to inject repeatedly more drugs percutaneously with a minimal invasion. The main objective of this study was to develop such a drug delivery system (DDS) for long-term control of discogenic LBP. The DDS consists of in situ forming hydrogel matrix (Pluronic F127 (R) plus sodium hyaluronate) containing microspheres (MS). The solid MS were used for long-term release of the drugs. Both hydrogel matrix and MS contained a model drug, bupivacaine base (BB). The phase transition (liquid at room temperature, gel at around body temperature) could be manipulated by changing the composition of the hydrogel. In vitro test showed that similar to 3% (w/w) of the BB loaded to MS were released during 42 days, demonstrating a good potential for sustained release of bupivacaine. (C) 2009 Wiley Periodicals, Inc. J Biomed Mater Res 92A: 378-385, 2010